Physician profile
Mark Eric Leimbach
NPI 1104878404
$8,813.46
in general payments reported to CMS, 2019-2025
32 companies · $2,557 in 2025
The $2,557 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,471 · 2020: $697 · 2021: $951 · 2022: $920 · 2023: $1,389 · 2024: $829 · 2025: $2,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,433 · Travel and Lodging: $1,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,432.72 |
| Travel and Lodging | $1,342.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,032.63 | 2021-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $1,842.98 | 2019-2025 | Watchman Flx, Watchman Access System |
| Abbott Laboratories | $884.18 | 2019-2024 | Dragonfly Opstar, Cardiomems, Portico |
| Medtronic, INC. | $445.27 | 2021-2025 | Micra, Corevalve Evolut R |
| Janssen Pharmaceuticals, INC | $363.98 | 2019-2022 | |
| Amgen INC. | $357.98 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $338.95 | 2021-2025 | |
| Biotronik INC. | $322.34 | 2022-2023 | Acticor 7 Vr-T Dx |
| Abiomed | $244.05 | 2024-2025 | Impella |
| Angiodynamics, INC. | $211.80 | 2023-2024 | Alphavac |
| Medtronic Vascular, INC. | $207.11 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $205.66 | 2021-2025 | |
| Esperion Therapeutics, INC. | $174.82 | 2021-2024 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $134.84 | 2020-2021 | |
| Avinger INC. | $118.92 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $112.04 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $106.38 | 2021-2024 | Farxiga |
| Ge Healthcare | $105.52 | 2020 | |
| Cvrx, INC. | $79.35 | 2023-2025 | Barostim Neo System |
| Shockwave Medical, INC | $72.00 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Alnylam Pharmaceuticals INC. | $63.48 | 2020-2025 | Amvuttra |
| Actelion Pharmaceuticals US, INC. | $59.66 | 2021-2023 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $56.68 | 2022-2025 | Capvaxive, Verquvo |
| E.R. Squibb & Sons, L.L.C. | $52.55 | 2019-2024 | Eliquis |
| Heartflow, INC. | $51.69 | 2023-2024 | Ffrct |
| Scpharmaceuticals INC. | $35.22 | 2025 | |
| Novo Nordisk INC | $33.38 | 2021-2025 | Wegovy |
| Chiesi USA, INC. | $27.56 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $24.70 | 2024 | |
| Lantheus Medical Imaging, INC. | $22.23 | 2023 | Definity |
| La Jolla Pharmaceutical Company | $15.62 | 2025 | Giapreza |
| Altathera Pharmaceuticals LLC | $9.89 | 2025 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Leimbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.